Tema Etfs LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX

Tema Etfs LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.6% during the third quarter, HoldingsChannel.com reports. The firm owned 9,651 shares of the pharmaceutical company’s stock after purchasing an additional 1,583 shares during the period. Tema Etfs LLC’s holdings in Vertex Pharmaceuticals were worth $3,780,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Costello Asset Management INC grew its stake in shares of Vertex Pharmaceuticals by 3.6% during the second quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company’s stock valued at $307,000 after buying an additional 24 shares during the last quarter. Kovack Advisors Inc. grew its position in Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock valued at $570,000 after acquiring an additional 24 shares during the last quarter. Newman Dignan & Sheerar Inc. grew its position in Vertex Pharmaceuticals by 3.3% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after acquiring an additional 25 shares during the last quarter. Eastern Bank increased its stake in Vertex Pharmaceuticals by 1.6% in the second quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company’s stock worth $728,000 after purchasing an additional 25 shares during the period. Finally, Washington Trust Advisors Inc. lifted its position in shares of Vertex Pharmaceuticals by 8.4% during the second quarter. Washington Trust Advisors Inc. now owns 323 shares of the pharmaceutical company’s stock worth $144,000 after purchasing an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 63,781 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total value of $28,650,425.20. Following the transaction, the chairman owned 24,026 shares of the company’s stock, valued at $10,792,479.20. The trade was a 72.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ourania Tatsis sold 4,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $474.99, for a total transaction of $2,137,455.00. Following the sale, the executive vice president directly owned 42,293 shares of the company’s stock, valued at $20,088,752.07. The trade was a 9.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 165,105 shares of company stock worth $73,858,523 over the last quarter. Insiders own 0.20% of the company’s stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported progress advancing suzetrigine into a Phase‑3 trial for diabetic nerve pain — a meaningful new indication that could broaden revenue beyond its cystic fibrosis franchise. Vertex Advances Suzetrigine Phase 3 Trial
• Positive Sentiment: Wolfe Research upgraded the stock recently, and several sell‑side firms have raised price targets (e.g., Leerink, Wells Fargo), supporting upside expectations and a consensus target near ~$504. Vertex Stock Rating Upgraded by Wolfe Research
• Neutral Sentiment: Market recaps note short‑term price weakness even as fundamentals and analyst coverage remain constructive — context for volatile daily moves but not necessarily a change to the longer‑term thesis. Vertex Stock Dips While Market Gains: Key Facts
• Neutral Sentiment: Another market note highlighted the recent down‑day versus a broader market uptick — useful color for traders but not new company‑specific catalysts. Vertex Stock Falls Amid Market Uptick
• Negative Sentiment: Two senior executives disclosed sizable open‑market sales this week — EVP Charles Wagner Jr. sold 9,532 shares (~$4.4M at ~$461/share) and EVP Ourania Tatsis sold 4,500 shares (~$2.14M at ~$475/share). Large insider sales can pressure sentiment even if not tied to company fundamentals. Charles Wagner, Jr. Sells 9,532 Shares
• Negative Sentiment: Separate filing shows EVP Ourania Tatsis’ 4,500‑share sale and a near‑10% reduction in her position — another factor likely weighing on intraday selling pressure. Ourania Tatsis Insider Sale
• Negative Sentiment: A Seeking Alpha piece and some sell‑side notes discuss the near‑term cost and execution risk of expanding beyond cystic fibrosis, which can temper investor appetite until new indications (like suzetrigine) de‑risk. The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $463.86 on Monday. The company has a market cap of $117.69 billion, a PE ratio of 32.71 and a beta of 0.31. The firm’s 50 day moving average price is $443.50 and its 200-day moving average price is $427.04. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.22. The business had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the firm earned $4.38 EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VRTX shares. Leerink Partners upped their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, December 29th. UBS Group assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 6th. They issued a “buy” rating and a $535.00 target price on the stock. Wolfe Research raised shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price on the stock in a research report on Tuesday, January 6th. JPMorgan Chase & Co. boosted their price target on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a report on Wednesday, October 8th. Finally, Barclays raised their price objective on Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $503.80.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.